|
ALZN Alzamend Neuro Inc 1677077 |
| Income Statement |
|
Net Income
|
2026-01-31
|
$-2,198,991.00 |
| Balance Sheet |
|
Current Assets
|
$3,699,282.00 |
|
Assets
|
$4,041,833.00 |
|
Current Liabilities
|
$3,826,457.00 |
|
Liabilities
|
$1,857,328.00 |
|
Equity
|
$2,184,505.00 |
|
Shares Out
|
3804741.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-5,270,519.00 |
|
Investing Cash Flow
|
$-300,000.00 |
| Market Analysis |
Market Cap
|
$5,136,400.35 |
|
Price
|
$1.33 |
|
BVPS
|
0.57 |
|
PB
|
2.37 |
|
EPS
|
-0.58 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:46 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:47 |
|
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view ALZN documents filed with the SEC.
ALZN Filings
Clear
